Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Stud Health Technol Inform ; 310: 1086-1090, 2024 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-38269982

RESUMEN

Clinical trial enrollment is impeded by the significant time burden placed on research coordinators screening eligible patients. With 50,000 new cancer cases every year, the Veterans Health Administration (VHA) has made increased access for Veterans to high-quality clinical trials a priority. To aid in this effort, we worked with research coordinators to build the MPACT (Matching Patients to Accelerate Clinical Trials) platform with a goal of improving efficiency in the screening process. MPACT supports both a trial prescreening workflow and a screening workflow, employing Natural Language Processing and Data Science methods to produce reliable phenotypes of trial eligibility criteria. MPACT also has a functionality to track a patient's eligibility status over time. Qualitative feedback has been promising with users reporting a reduction in time spent on identifying eligible patients.


Asunto(s)
Neoplasias , Tecnología , Humanos , Flujo de Trabajo , Ciencia de los Datos , Determinación de la Elegibilidad , Neoplasias/diagnóstico , Neoplasias/terapia
2.
J Expo Sci Environ Epidemiol ; 32(3): 442-450, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-34625714

RESUMEN

BACKGROUND: Water arsenic (As) sources beyond a rural household's primary well may be a significant source for certain individuals, including schoolchildren and men working elsewhere. OBJECTIVE: To improve exposure assessment by estimating the fraction of drinking water that comes from wells other than the household's primary well in a densely populated area. METHODS: We use well water and urinary As data collected in 2000-2001 within a 25 km2 area of Araihazar upazila, Bangladesh, for 11,197 participants in the Health Effects of Arsenic Longitudinal Study (HEALS). We estimate the fraction of water that participants drink from different wells by imposing a long-term mass-balance constraint for both As and water. RESULTS: The mass-balance model suggest that, on average, HEALS participants obtain 60-75% of their drinking water from their primary household wells and 25-40% from other wells, in addition to water from food and cellular respiration. Because of this newly quantified contribution from other wells, As in drinking water rather than rice was identified as the largest source of As exposure at baseline for HEALS participants with a primary household well containing ≤50 µg/L As. SIGNIFICANCE: Dose-response relationships for As based on water As should take into account other wells. The mass-balance approach could be applied to study other toxicants.


Asunto(s)
Arsénico , Agua Potable , Contaminantes Químicos del Agua , Arsénico/análisis , Bangladesh , Niño , Agua Potable/análisis , Exposición a Riesgos Ambientales/análisis , Humanos , Estudios Longitudinales , Masculino , Contaminantes Químicos del Agua/análisis , Abastecimiento de Agua
3.
JAMA Oncol ; 8(2): 281-286, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-34854921

RESUMEN

Importance: Patients with cancer are at increased risk for severe COVID-19, but it is unknown whether SARS-CoV-2 vaccination is effective for them. Objective: To determine the association between SARS-CoV-2 vaccination and SARS-CoV-2 infections among a population of Veterans Affairs (VA) patients with cancer. Design, Setting, and Participants: Retrospective, multicenter, nationwide cohort study of SARS-CoV-2 vaccination and infection among patients in the VA health care system from December 15, 2020, to May 4, 2021. All adults with solid tumors or hematologic cancer who received systemic cancer-directed therapy from August 15, 2010, to May 4, 2021, and were alive and without a documented SARS-CoV-2 positive result as of December 15, 2020, were eligible for inclusion. Each day between December 15, 2020, and May 4, 2021, newly vaccinated patients were matched 1:1 with unvaccinated or not yet vaccinated controls based on age, race and ethnicity, VA facility, rurality of home address, cancer type, and treatment type/timing. Exposures: Receipt of a SARS-CoV-2 vaccine. Main Outcomes and Measures: The primary outcome was documented SARS-CoV-2 infection. A proxy for vaccine effectiveness was defined as 1 minus the risk ratio of SARS-CoV-2 infection for vaccinated individuals compared with unvaccinated controls. Results: A total of 184 485 patients met eligibility criteria, and 113 796 were vaccinated. Of these, 29 152 vaccinated patients (median [IQR] age, 74.1 [70.2-79.3] years; 95% were men; 71% were non-Hispanic White individuals) were matched 1:1 to unvaccinated or not yet vaccinated controls. As of a median 47 days of follow-up, 436 SARS-CoV-2 infections were detected in the matched cohort (161 infections in vaccinated patients vs 275 in unvaccinated patients). There were 17 COVID-19-related deaths in the vaccinated group vs 27 COVID-19-related deaths in the unvaccinated group. Overall vaccine effectiveness in the matched cohort was 58% (95% CI, 39% to 72%) starting 14 days after the second dose. Patients who received chemotherapy within 3 months prior to the first vaccination dose were estimated to have a vaccine effectiveness of 57% (95% CI, -23% to 90%) starting 14 days after the second dose vs 76% (95% CI, 50% to 91%) for those receiving endocrine therapy and 85% (95% CI, 29% to 100%) for those who had not received systemic therapy for at least 6 months prior. Conclusions and Relevance: In this cohort study, COVID-19 vaccination was associated with lower SARS-CoV-2 infection rates in patients with cancer. Some immunosuppressed subgroups may remain at early risk for COVID-19 despite vaccination, and consideration should be given to additional risk reduction strategies, such as serologic testing for vaccine response and a third vaccine dose to optimize outcomes.


Asunto(s)
COVID-19 , Neoplasias , Veteranos , Adulto , Anciano , Vacunas contra la COVID-19 , Estudios de Cohortes , Humanos , Masculino , Estudios Retrospectivos , SARS-CoV-2 , Vacunación
4.
Geoderma ; 3822021 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-33162565

RESUMEN

Rice is the primary crop in Bangladesh and rice yield is diminished due to the buildup of arsenic (As) in soil from irrigation with high-As groundwater. Soil testing with an inexpensive kit could help farmers target high-As soil for mitigation or decide to switch to a different crop that is less sensitive to As in soil. A total of 3,240 field kit measurements of As in 0.5 g of fresh soil added to 50 mL of water were compared with total soil As concentrations measured on oven-dried homogenized soil by X-ray fluorescence (XRF). For sets of 12 soil samples collected within a series of rice fields, the average of kit As measurements was a linear function of the average of XRF measurements (r2=0.69). Taking into account that the kit overestimates water As concentrations by about a factor of two, the relationship suggests that about a quarter of the As in paddy soil is released in the kit's reaction vessel. Using the relationship and considering XRF measurements as the reference, the 12-sample average determined correctly whether soil As was above or below a 30 mg/kg threshold in 86% of cases where soil As was above the threshold and in 79% of cases where soil As was below the threshold. We also used a Bayesian approach using 12 kit measurements to estimate the probability that soil As was above a given threshold indicated by XRF measurements. The Bayesian approach is theoretically optimal but was only slightly more accurate than the linear regression. These results show that rice farmers can identify high-As portions of their fields for mitigation using a dozen field kit measurements on fresh soil and base their decisions on this information.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...